Cargando…
Redefining serological diagnostics with immunoaffinity proteomics
Serological diagnostics is generally defined as the detection of specific human immunoglobulins developed against viral, bacterial, or parasitic diseases. Serological tests facilitate the detection of past infections, evaluate immune status, and provide prognostic information. Serological assays wer...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568870/ https://www.ncbi.nlm.nih.gov/pubmed/37821808 http://dx.doi.org/10.1186/s12014-023-09431-y |
_version_ | 1785119444539801600 |
---|---|
author | Walter, Jonathan Eludin, Zicki Drabovich, Andrei P. |
author_facet | Walter, Jonathan Eludin, Zicki Drabovich, Andrei P. |
author_sort | Walter, Jonathan |
collection | PubMed |
description | Serological diagnostics is generally defined as the detection of specific human immunoglobulins developed against viral, bacterial, or parasitic diseases. Serological tests facilitate the detection of past infections, evaluate immune status, and provide prognostic information. Serological assays were traditionally implemented as indirect immunoassays, and their design has not changed for decades. The advantages of straightforward setup and manufacturing, analytical sensitivity and specificity, affordability, and high-throughput measurements were accompanied by limitations such as semi-quantitative measurements, lack of universal reference standards, potential cross-reactivity, and challenges with multiplexing the complete panel of human immunoglobulin isotypes and subclasses. Redesign of conventional serological tests to include multiplex quantification of immunoglobulin isotypes and subclasses, utilize universal reference standards, and minimize cross-reactivity and non-specific binding will facilitate the development of assays with higher diagnostic specificity. Improved serological assays with higher diagnostic specificity will enable screenings of asymptomatic populations and may provide earlier detection of infectious diseases, autoimmune disorders, and cancer. In this review, we present the major clinical needs for serological diagnostics, overview conventional immunoassay detection techniques, present the emerging immunoassay detection technologies, and discuss in detail the advantages and limitations of mass spectrometry and immunoaffinity proteomics for serological diagnostics. Finally, we explore the design of novel immunoaffinity-proteomic assays to evaluate cell-mediated immunity and advance the sequencing of clinically relevant immunoglobulins. |
format | Online Article Text |
id | pubmed-10568870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105688702023-10-13 Redefining serological diagnostics with immunoaffinity proteomics Walter, Jonathan Eludin, Zicki Drabovich, Andrei P. Clin Proteomics Review Serological diagnostics is generally defined as the detection of specific human immunoglobulins developed against viral, bacterial, or parasitic diseases. Serological tests facilitate the detection of past infections, evaluate immune status, and provide prognostic information. Serological assays were traditionally implemented as indirect immunoassays, and their design has not changed for decades. The advantages of straightforward setup and manufacturing, analytical sensitivity and specificity, affordability, and high-throughput measurements were accompanied by limitations such as semi-quantitative measurements, lack of universal reference standards, potential cross-reactivity, and challenges with multiplexing the complete panel of human immunoglobulin isotypes and subclasses. Redesign of conventional serological tests to include multiplex quantification of immunoglobulin isotypes and subclasses, utilize universal reference standards, and minimize cross-reactivity and non-specific binding will facilitate the development of assays with higher diagnostic specificity. Improved serological assays with higher diagnostic specificity will enable screenings of asymptomatic populations and may provide earlier detection of infectious diseases, autoimmune disorders, and cancer. In this review, we present the major clinical needs for serological diagnostics, overview conventional immunoassay detection techniques, present the emerging immunoassay detection technologies, and discuss in detail the advantages and limitations of mass spectrometry and immunoaffinity proteomics for serological diagnostics. Finally, we explore the design of novel immunoaffinity-proteomic assays to evaluate cell-mediated immunity and advance the sequencing of clinically relevant immunoglobulins. BioMed Central 2023-10-12 /pmc/articles/PMC10568870/ /pubmed/37821808 http://dx.doi.org/10.1186/s12014-023-09431-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Walter, Jonathan Eludin, Zicki Drabovich, Andrei P. Redefining serological diagnostics with immunoaffinity proteomics |
title | Redefining serological diagnostics with immunoaffinity proteomics |
title_full | Redefining serological diagnostics with immunoaffinity proteomics |
title_fullStr | Redefining serological diagnostics with immunoaffinity proteomics |
title_full_unstemmed | Redefining serological diagnostics with immunoaffinity proteomics |
title_short | Redefining serological diagnostics with immunoaffinity proteomics |
title_sort | redefining serological diagnostics with immunoaffinity proteomics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568870/ https://www.ncbi.nlm.nih.gov/pubmed/37821808 http://dx.doi.org/10.1186/s12014-023-09431-y |
work_keys_str_mv | AT walterjonathan redefiningserologicaldiagnosticswithimmunoaffinityproteomics AT eludinzicki redefiningserologicaldiagnosticswithimmunoaffinityproteomics AT drabovichandreip redefiningserologicaldiagnosticswithimmunoaffinityproteomics |